BAT 2541.27p About us Our products How we work Sustainability Investors Media Reporting Careers Our Scientific Research Director’s view As a business, we are at the scientific forefront Dr David O’Reilly explains how BAT’s world-class science is driving our transformation Science is the driving force of today’s society and scientists are forever pushing at the boundaries to discover solutions that will transform all of our lives. The pandemic showed us that science has never been more important to the way we live, work, and function. It protects us in ways that we sometimes overlook which is why, across the world, the work of scientists is being studied and celebrated with increased excitement. As a business, we are also at that scientific forefront, demonstrating a relentless commitment to our core purpose – to build A Better Tomorrow™ for our consumers, society, employees, and shareholders. Despite the challenges we have all faced in these past months, our team has continued to focus on how science can move us towards that purpose and we invest over £350 million each year in R&D. Through our dedication to science and diverse skills we undertake a broad range of activities, such as running COVID-19 testing for some of the local NHS services near our R&D headquarters, to generating new evidence about our products. This is the evidence that helps us to scientifically substantiate their role in tobacco harm reduction and, we hope, encourage and enable current smokers to stop smoking combustible cigarettes and completely switch to a reduced-risk*† alternative. Our biotech subsidiary is also continuing its pioneering work on a candidate vaccine for COVID-19, which we hope can help play a role in fighting this global pandemic and its after-effects. It forms part of our small but emerging vaccines portfolio and sits alongside our candidate Quadrivalent Influenza Vaccine (QIV), which is in Phase I. In 2020, we also announced our plans to go Beyond Nicotine, providing adult consumers with products to stimulate their senses. This coincided with the launch of our first CBD vaping product. Our Science & Innovation Report outlines some of the major achievements BAT has delivered through science and innovation. By reflecting on them, we can better understand our future and share how we are moving into a bold new era of consumer products, cutting-edge science and next-level digital capabilities. We are committed to making a step change in our New Category products performance and in our sustainability ambition. Reducing the health impact of our business is our principal focus and we are also committed to helping address climate change and protecting the environment. This is just the start, as I know we want to deliver more transformative benefits, proving how relentless we are in our pursuit of excellence, and our commitment to ground-breaking science. *Any reference to ‘reduced-risk products’ is based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive. † Our products as sold in the US, including Vuse, Velo, Grizzly, Kodiak, and Camel Snus, are subject to Food and Drug Administration (FDA) regulation and no reduced-risk claims will be made as to these products without FDA clearance. About us We are BAT Our purpose and strategy A sustainable approach World-class science Our Scientific Research Director’s view Sixty years of science Leaf research R&D virtual tour Harm reduction People and culture Meet the Board Corporate governance Policies, principles and standards Our history - a timeline Home About us World-class science Our Scientific Research Director’s view Follow us Latest tweets BAT @BATplc #ICYMI: BAT’s commitment to #diversity and #inclusion has been rewarded with a significant piece of recognition. W… twitter.com/i/web/status/1… 26 Nov Check out our Quarterly Science Updates to find out more about the #science and accelerating BAT's… twitter.com/i/web/status/1… 25 Nov Current UK share price 2541.27p -70.23p 26 Nov 2021 16:45 Quick Links Modern Slavery Statement Gender Pay Report Annual Report Sustainability Report Science and Technology Report Share price data Worldwide websites Standards of Business Conduct Site map Contact us BAT Globe House 4 Temple Place London WC2R 2PG +44 (0) 20 7845 1000 Accessibility Privacy Notice Cookie Notice Conditions of use Financial information We collect and store information on your device when you use this website including setting cookies. Some are essential, while others are used to enhance your experience, and to operate and improve the website. You can withdraw your consent at any time for non-strictly necessary cookies. Please choose the accept all button if you consent for us to use these non-strictly necessary cookies and the personal information they collect for the purposes described in our Cookie Notice. Accept all cookies Disable non-essential Customise settings